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A Periplasmic Drug-Binding Site of the AcrB Multidrug Efflux Pump: a
Crystallographic and Site-Directed Mutagenesis Study
Abstract
The Escherichia coli AcrB multidrug efflux pump is a membrane protein that recognizes many structurally
dissimilar toxic compounds. We previously reported the X-ray structures of four AcrB-ligand complexes in
which the ligands were bound to the wall of the extremely large central cavity in the transmembrane domain
of the pump. Genetic studies, however, suggested that discrimination between the substrates occurs mainly in
the periplasmic domain rather than the transmembrane domain of the pump. We here describe the crystal
structures of the AcrB mutant in which Asn109 was replaced by Ala, with five structurally diverse ligands,
ethidium, rhodamine 6G, ciprofloxacin, nafcillin, and Phe-Arg-β-naphthylamide. The ligands bind not only to
the wall of central cavity but also to a new periplasmic site within the deep external depression formed by the
C-terminal periplasmic loop. This depression also includes residues identified earlier as being important in the
specificity. We show here that conversion into alanine of the Phe664, Phe666, or Glu673 residue in the
periplasmic binding site produced significant decreases in the MIC of most agents in the N109A background.
Furthermore, decreased MICs were also observed when these residues were mutated in the wild-type AcrB
background, although the effects were more modest. The MIC data were also confirmed by assays of ethidium
influx rates in intact cells, and our results suggest that the periplasmic binding site plays a role in the
physiological process of drug efflux.
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The Escherichia coli AcrB multidrug efflux pump is a membrane protein that recognizes many structurally
dissimilar toxic compounds. We previously reported the X-ray structures of four AcrB-ligand complexes in
which the ligands were bound to the wall of the extremely large central cavity in the transmembrane domain
of the pump. Genetic studies, however, suggested that discrimination between the substrates occurs mainly in
the periplasmic domain rather than the transmembrane domain of the pump. We here describe the crystal
structures of the AcrB mutant in which Asn109 was replaced by Ala, with five structurally diverse ligands,
ethidium, rhodamine 6G, ciprofloxacin, nafcillin, and Phe-Arg--naphthylamide. The ligands bind not only to
the wall of central cavity but also to a new periplasmic site within the deep external depression formed by the
C-terminal periplasmic loop. This depression also includes residues identified earlier as being important in the
specificity. We show here that conversion into alanine of the Phe664, Phe666, or Glu673 residue in the
periplasmic binding site produced significant decreases in the MIC of most agents in the N109A background.
Furthermore, decreased MICs were also observed when these residues were mutated in the wild-type AcrB
background, although the effects were more modest. The MIC data were also confirmed by assays of ethidium
influx rates in intact cells, and our results suggest that the periplasmic binding site plays a role in the
physiological process of drug efflux.
Multidrug transporters cause serious problems in the che-
motherapy of cancer as well as in the antibiotic treatment of
bacterial infections. These membrane proteins recognize many
structurally dissimilar toxic compounds and actively extrude
them from cells. The Escherichia coli AcrB transporter (17,
18), which is a member of the resistance-nodulation-division
(RND) family transporters (42) and is responsible for most of
the intrinsic drug resistance of this organism (28, 29, 37), is one
of the best-studied multidrug pumps. It occurs as a multipro-
tein complex (40, 41, 50) with the outer membrane channel
TolC (9, 15) and a periplasmic linker protein, AcrA (17) (the
structure of an AcrA homolog, MexA, was solved recently [2,
11]), and this complex structure allows the direct export of
drugs to the external medium (28). The structural work of
Murakami et al. (23) revealed that the unliganded AcrB is a
homotrimer, where each subunit contains 12 transmembrane
(TM) helices and two large periplasmic domains (each exceed-
ing 300 residues) between TM helices TM1 and TM2 and
between TM7 and TM8. The periplasmic domains of AcrB
form a funnel-like structure at the top which is thought (23) to
associate with the end of the periplasmic tunnel of TolC (15)
and a connected “pore” at the center (Fig. 1A). The pore leads
down to the large central cavity, with a diameter of 35 Å,
formed by the TM domains of the three protomers. The cen-
tral cavity is connected also to the periplasm through three
vestibules located at subunit interfaces (Fig. 1A). These vesti-
bules have been suggested to allow direct access of drugs to the
central cavity from the periplasm as well as from the outer
leaflet of the cytoplasmic membrane.
We showed that four different drugs, ciprofloxacin, dequal-
inium, rhodamine 6G, and ethidium, were indeed bound to the
wall of the upper portion of the central cavity (48), as predicted
by this model. However, this binding presumably corresponds
to the first step in the drug extrusion process, because the drug
molecules have to be transported to the tip of the periplasmic
domain to enter the TolC channel. The most direct route for
this drug transport is through the central pore of the periplas-
mic domain of AcrB (Fig. 1A), but the pore is closed in the
crystal structure (23). Because the Asn 109 side chain pro-
trudes prominently into the pore interior, we thought that the
channel might be opened up by mutating this residue to ala-
nine. Unexpectedly, this N109A mutant AcrB, which was
largely functional, was found to bind ligands not only to the
central cavity but also to a new, periplasmic binding site within
the prominent depression on the outside surface of the
periplasmic domain (Fig. 1A and B). This result is interesting,
because previous genetic studies involving domain swapping
(7, 8, 39) and random mutagenesis in Pseudomonas aeruginosa
AcrB homologs MexD and MexB (19, 20) showed that the
periplasmic domain, rather than the TM domain, of these
transporters played a major role in the determination of sub-
strate specificity and hence in substrate binding.
This paper documents the binding of various drugs to this
new periplasmic site of N109A mutant AcrB and shows by
site-directed mutagenesis that alteration of some of the resi-
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dues at this periplasmic binding site indeed decreases the drug
efflux activity of the pump.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Bacterial strains and plas-
mids used in this work are listed in Table 1. E. coli DH5 was used for con-
struction and propagation of various plasmid constructs. Cells were grown at
37°C with agitation in Luria-Bertani broth (LB) (Difco) supplemented with
ampicillin (100 g/ml) (Sigma) when necessary.
Molecular biology techniques. Plasmid DNA was routinely prepared by using
a QIAGEN Plasmid Miniprep kit (QIAGEN Inc.). Transformation of E. coli
strain DH5 or HNCE1b with plasmid DNA was performed by heat shock
treatment of competent cells. DNA sequencing was performed on double-
stranded DNA templates by the use of universal primers or custom primers
(Invitrogen). Nucleotide sequences were determined by Elim Biopharmaceuti-
cals Inc. DNA alignments were obtained by using the BLASTN 2.02 program (3)
provided by the National Center for Biotechnology Information.
Construction of the N109A mutant acrB gene. The Asn109 residue of E. coli
AcrB was changed into Ala by site-directed mutagenesis using a QuikChange kit
(Stratagene) with the plasmid pUC151A (17). The mutated gene was sequenced
completely to make certain that no other mutations were introduced during the
PCR.
Purification of AcrB. The native AcrB and N109A mutant AcrB proteins (both
without “tags”) were purified following procedures similar to those described
earlier (47, 49).
The N109A mutant AcrB was overproduced in E. coli C43(DE3) cells (21) by
the use of the plasmid derived from pUC151A. Cells were grown in 10 liters of
LB medium with 100 g/ml ampicillin. Cells were disrupted with a French
FIG. 1. The structure of the AcrB trimer cocrystallized with ciprofloxacin. The three protomers are shown in blue, mauve, and green, and the
ciprofloxacin molecules are shown as CPK models. A. The wild-type AcrB trimer (from PDB file 1OYE). The locations of the “funnel,” “pore,”
and “central cavity” (defined in reference 23) are shown in dotted lines. The entrances to the surface cavities, “depression,” and “fissure” (in the
latter case, the right-hand entrance as viewed from the outside of the trimer) are shown in continuous lines. B. The N109A mutant AcrB trimer
(this study). The figures were drawn with Accelrys Viewer Pro and POV-RAY 3.5.
TABLE 1. Strains and plasmids
Strain
or plasmid Description or genotype
Reference
or source
Strain
DH5 F 80lacZM15 (lacZYA-argF)
U169 endA1 recA1 hsdR17 (rK
,
mK
) supE44 thi-1 gyrA96 relA1
phoA
33
CE43(DE3) Membrane protein overproducer
selected from BL21(DE3) [E.
coli B F ompT hsdSB gal dcm
(DE3)]
21
HNCE1b marR1 acrA::cat acrB::kan
acrD
5
Plasmid
pUC151A A 6.5-kb bglII fragment containing
the entire acrAB operon cloned
into pUC19 vector
17
pAcrB acrB gene cloned into pSportI
high-copy-number cloning and
expression vector; amp, lac-
inducible expression
5
pAcrAB pAcrB containing acrA gene
cloned upstream of acrB
This study
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pressure cell. The membrane was collected and washed twice with high-salt
buffer containing 20 mM sodium phosphate (pH 7.2), 2 M KCl, 10% glycerol, 1
mM EDTA, and 1 mM phenylmethanesulfonyl fluoride and once with 20 mM
HEPES-NaOH buffer (pH 7.5) containing 1 mM phenylmethanesulfonyl fluo-
ride. The purified membrane protein was solubilized in 1% (wt/vol) N-dodecyl-
-D-maltoside. Insoluble materials were removed by ultracentrifugation at
370,000  g. The extracted protein was purified with hydroxyapatite, Cu2
affinity (49), and G-200 sizing columns.
Crystallography. Liganded AcrB crystals were grown by cocrystallization with
ligands as described earlier (48). Thus, crystals of the N109A mutant were grown
by sitting-drop vapor diffusion at 25°C. A protein solution containing 24 mg/ml
N109A protein in 20 mM Tris (pH 8.0)–0.1% N-dodecyl--D-maltoside–20 mM
dithiothreitol was mixed with an equal volume of a reservoir solution containing
8 to 10% polyethyleneglycol 3000, 40 mM potassium citrate (pH 6.5), and 10%
glycerol. To ensure that more than one ligand molecule would bind to the
transporter, the ligand-to-protein (trimer) molar ratio in all complex-crystal
drops was set to 2:1. This corresponds to a total ligand concentration of about
120 M. Crystals appeared in the drops within 4 days. Cryoprotection was
achieved by raising the glycerol concentration stepwise up to 35% with a 5%
increment in each step.
All X-ray intensity data sets were collected at the Advanced Light Source
(Beamline 8.2.2) at a cryogenic temperature (100°K). The diffraction data were
processed with DENZO and scaled with SCALEPACK (30). The crystals of the
N109A mutant took the R32 space group with unit cell dimensions listed in Table
1. Initially, the overall structures of the N109A mutant were determined by
molecular replacement using a MolRep program (43) in the CCP4 package. The
wild-type AcrB structure (1OY6) with residues 7 to 498, 513 to 710, 712 to 859,
and 869 to 1,036 was used as a search model. Before refinement, 5% of all data
were set aside for cross-validation (4). The model refinements were performed
using the program Refmac (26) in the CCP4 package, and model rebuilding was
conducted using the program O (12).
Construction of plasmid pAcrAB. Oligonucleotide primers engineered with
SalI and SmaI restriction sites were used to amplify, by PCR, the acrA wild-type
gene under standard conditions using Pfu Ultra (Stratagene). The amplified
DNA was purified, digested sequentially by SalI and SmaI restriction enzymes
(New England Biolabs Inc.), and ligated into a similarly digested pAcrB plasmid
(8) so that the acrA gene would be located upstream of acrB, with an intergenic
distance of 30 nucleotides, and so that both genes would be under the control of
the lac promoter of vector pSport1.
Site-specific mutagenesis. Point mutations were introduced into the acrB gene
carried by plasmid pAcrB by the use of sense and antisense mutagenic primers
in a one-step PCR procedure. Approximately 10 to 20 ng of plasmid DNA from
E. coli served as the template for PCRs. The PCR mixture was composed of 1
M of each primer, 6% dimethyl sulfoxide, each deoxynucleoside triphosphate at
a concentration of 250 M in 1 PCR buffer, and 1.25 U of Pfu DNA polymer-
ase (Stratagene) in a final volume of 50 l. The PCR program was 1 min at 95°C
followed by 20 cycles of 30 s at 94°C, 30 s at 45°C, and 8 min at 68°C and an 8-min
final extension at 68°C. Then, the PCR product was treated with DpnI restriction
enzyme (New England Biolabs Inc.) to digest template DNA and to allow the
enrichment of newly synthesized DNA containing the desired mutation. The
digested DNA was used for transformation of E. coli strains DH5 by the cold
CaCl2 procedure (33). Plasmid DNA was extracted, sequenced to ensure the
presence of the desired mutation. The intact acrA gene was then inserted ahead
of the mutated acrB gene to produce pAcrAB-like plasmids, which were used for
trans complementation of strain HNCE1b.
Drug susceptibility assays. The susceptibilities to antimicrobial agents of E.
coli strains (inoculum, 500 cells/ml) harboring pAcrAB-derived plasmids were
determined by the twofold dilution method with LB agar medium containing 0.1
mM IPTG (isopropyl--D-thiogalactopyranoside). Bacterial growth was exam-
ined after 18 to 24 h at 37°C. Each assay was repeated at least five times to ensure
the reproducibility of the results.
Accumulation assay. Cells were grown overnight at 37°C, diluted 100-fold in
LB, and grown 1 h before the addition of 0.1 mM IPTG. When the cell suspen-
sion optical density at 600 nm reached 0.7 to 0.9, cells were harvested at 5,000 
g for 10 min at room temperature, washed once with 50 mM sodium phosphate
buffer (pH 7.2), and resuspended in the same buffer at a cell optical density at
600 nm of 0.4. The accumulation of ethidium bromide was assayed as described
by Li et al. (16).
Analysis of AcrA and AcrB expression levels. Exponential-phase cells grown in
LB were harvested, resuspended in 50 mM sodium phosphate buffer (pH 7.2),
and broken by sonication. Unbroken cells were removed by centrifugation at
10,000  g for 10 min. Total membrane extract was collected by ultracentrifu-
gation at 100,000 g for 30 min at 4°C. Proteins were resolved in sodium dodecyl
sulfate (SDS)-7.5% polyacrylamide gel electrophoresis. Alternatively, proteins
were transferred electrophoretically to nitrocellulose membrane (Bio-Rad) in
Tris base (20 mM)–glycine (150 mM)–methanol (20%) for Western blot analysis.
Binding of primary polyclonal antibody anti-AcrA or anti-AcrB (49) was de-
tected with an alkaline phosphate-conjugated anti-rabbit secondary antibody
(Sigma). Protein visualization was performed with nitroblue tetrazolium and
5-bromo-4-chloro-3-indolyl phosphate (5).
Protein structure accession numbers. The coordinates for the protein struc-
tures have been deposited in the Protein Data Bank (PDB) as 1T9T (N109A
mutant apoprotein), 1T9U (N109A-ciprofloxacin complex), 1T9V (N109A-rho-
damine 6G complex), 1T9W (N109A-nafcillin complex), 1T9X (N109A-ethidium
complex), and 1T9Y (N109A-Phe-Arg--naphthylamide complex).
RESULTS
Conversion of Asn109 residue into alanine. After the bind-
ing of the drug molecules to the central cavity (47, 48), the
most direct route for drug extrusion seemed to be through the
central pore, which is formed by the pore helices in the
periplasmic domain of AcrB, residues 102 to 115. However, in
AcrB these helices make a direct coiled-coil interaction at the
center of the three subunits (23, 48), and no channel is appar-
ent within the “pore.” Side chains of a few amino acid residues
protrude prominently into the center. Among these residues,
we thought that the three Asn109 side chains might interact
with each other. We therefore mutated this residue into ala-
nine by site-directed mutagenesis. The mutant AcrB was func-
tional in drug efflux, when expressed, together with AcrA, from
a pUC19-derived plasmid (17) or from a pSPORT1-derived
plasmid. The latter results are shown in Table 2 (top two rows).
As can be seen, the levels of resistance generated by the mu-
tant protein were nearly identical with those caused by the
unaltered AcrB, except for tetracycline, acriflavine, and SDS.
When expressed from pUC19-derived plasmid, both the mu-
tant and the unaltered AcrB raised the MIC of nafcillin (Naf)
from 	0.2 g/ml in the AcrB-deficient host strain to 
500
g/ml.
Structure of the mutant AcrB. We solved the three-dimen-
sional structure of the mutant AcrB, either alone or in a com-
plex with five different ligand molecules, by X-ray crystallog-
raphy through molecular replacement. Refinement resulted in
Rwork values between 25.6 and 28.0%, with a maximal resolu-
tion of 3.2 to 3.8 Å (Table 3). The overall structure of the
mutant protein was very similar to that of the wild-type AcrB.
In the mutant AcrB, an opening of 3 Å was created in the
central pore according to surface plots, whereas the pore was
totally closed in the wild-type AcrB (not shown). The loop
(residues 860 to 868) that connects the C-terminal end of the
C-terminal loop domain to TM helix 8 could not be modeled in
the wild-type AcrB (23, 48). In the crystals of N109A mutant
AcrB, however, these residues could be introduced into the
model with the help of simulated annealing omit maps. The
TM helices following this loop (TM8 through TM12) were
displaced in the mutant protein, and changes in tilt increased
the displacement to as much as 3.5 Å close to the C terminus
(Fig. 2).
The mutant protein was crystallized in the presence of five
different agents, ciprofloxacin (Cip), rhodamine 6G (R6G),
ethidium bromide (Et), Naf, and Phe-Arg--naphthylamide
(MC), an inhibitor of AcrB (32). The crystal structures showed
that these ligands, in addition to the central cavity, bound to a
second, novel binding site in the periplasmic domain, within
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the deep external depression formed by the C-terminal
periplasmic loop domain. The structure of Cip-N109A AcrB
complex is shown as an example in Fig. 1B. The simulated
annealing omit maps of Cip and R6G, bound to the central
cavity and periplasmic site, are shown as examples in Fig. 3.
Drug binding to the periplasmic binding pocket. The bind-
ing of the five different ligands to the periplasmic pocket is
shown in Fig. 4. All drugs bind to the same region of the
pocket, although Cip and R6G molecules extend more toward
the membrane and Naf further away from it. The “right” wall
(looking into the center of the trimer with its periplasmic
domain on top, as in Fig. 1) and a part of the bottom of the
binding pocket are formed by the loop (residues 663 to 680)
that connects the two subdomains (PC1 and PC2) (23) of the
C-terminal periplasmic loop. A short section of another loop
(residues 564 to 568), connecting TM7 helix with the periplas-
mic domain, also functions as the bottom of the pocket. The
wall on the opposite side is made of a short -strand (C6 of
reference 23) (residues 714 to 722) and another -strand
(C14 of reference 23) (residues 826 to 833). Four proline
residues, Pro718, Pro669, Pro565, and Pro833, surround the
pocket.
Figure 5 shows, as an example, the details of the Cip binding
in the predominant conformation we have modeled. The lim-
ited resolution makes detailed interpretation difficult. How-
ever, the ligand binding seems to be rather loose. Thus, there
are no clearly identifiable H-bonding interactions, and the bulk
of amino acid side chains appear to be several angstroms away
from the ligand. Nevertheless, in the model there seem to be
some electrostatic interactions, which are facilitated by the
apparent rotations of some side chains upon drug binding.
Thus, in our model, the side chain amide nitrogen of Asn719 is
close (3.7 Å) to the carboxylic acid oxygen of Cip, and the side
chain carbonyl oxygen of Asn667 is close (3.3 Å) to the pre-
sumably protonated piperazine nitrogen of Cip.
The drug binding also produces significant displacement of
several segments of the backbone. There is a large movement
of the segment between Val107 and Leu113 (including the
mutated residue Ala109), apparently because the segment be-
tween Gln104 and Gln108 becomes helical as a result of drug
binding. Some of the side chain atoms appear to become dis-
placed by nearly 3 Å upon drug binding. In addition, the
segment between Gly861 and Gly870, just preceding TM helix
FIG. 2. Overlay of the backbones of N109A (unliganded) and wild-
type AcrB (unliganded) proteins. The model of the unliganded N109A
AcrB (this work) was overlaid on the model of unliganded wild-type
AcrB determined by Murakami et al. (23), using the “magic fit” func-
tion of the DeepView program, and the N109A structure was colored
in rainbow colors; red shows the largest deviation and blue the smallest
deviation from the reference, wild-type AcrB structure. The A109
residue is shown as a red stick model (arrow). The reference structure
is not shown. The deviation at the N-terminal end of TM8 is about 1
Å, which gradually increases to about 2.5 Å at the end of TM12.
Although these values are small in comparison with the resolution of
the structure, they appear to be significant, because many consecutive
residues show a consistent pattern. The figure was created with Deep-
View and POV-RAY 3.5.
TABLE 3. Data collection and crystallographic analysis
Parameter
Data for indicated complex
N109A N109A-Cip N109A-R6G N109A-Naf N109A-Et N109A-MC
Space group R32 R32 R32 R32 R32 R32
Cell constants (Å) a  b  144.4,
c  518.9,
    90,
  120
a  b  144.1,
c  518.8,
    90,
  120
a  b  144.4,
c  518.4,
    90,
  120
a  b  144.5,
c  519.4,
    90,
  120
a  b  145.0,
c  519.4,
    90,
  120
a  b  144.9,
c  516.7,
    90,
  120
Resolution (Å) 3.27 (3.44–3.27) 3.23 (3.55–3.23) 3.82 (4.00–3.82) 3.27 (3.44–3.27) 3.20 (3.40–3.20) 3.56 (3.78–3.56)
Completeness (%) 99.6 (98.9) 100 (99.2) 100 (98.6) 96.8 (94.5) 100 (99.1) 100 (99.4)
Rsym (%) 8.6 (48.2) 7.2 (29.3) 10.4 (48.2) 10.3 (38.1) 9.7 (37.6) 10.1 (47.8)
Rwork/Rfree (%) 26.7/33.3 26.6/33.6 28.0/33.5 26.7/34.9 27.2/34.1 25.6/33.3
Total no. of reflections 874,453 448,795 374,468 1,288,255 894,586 464,493
No. of unique reflections 42,155 37,827 25,859 39,543 42,277 34,163
I/(I) 2.2 3.0 2.8 1.6 2.4 2.1
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8, shows a slight backbone displacement and side chain move-
ment up to 3 Å.
Similar interactions often involving the same set of residues
appear to occur with the binding of R6G and Et in our model
(not shown). Surprisingly, no acidic residue that would neu-
tralize the positive charges of these dyes was found within 6 Å
of the ligand (except Asp566, which is close to the benzoic acid
moiety of R6G but more than 11 Å away from its amine
nitrogens), although the partially negative -electron cloud of
the phenyl ring of Phe664 is about 4  from these dyes. The
charged atoms may also interact with the backbone oxygens
(possibly of Leu828, Gly829, and Ser715), as well as the side
chain oxygens of some residues (possibly Ser715 and Gln830).
Interestingly, positive charges of pentamidine were recently
found to interact exclusively with partial negative charges of
oxygens in the backbone and the hydroxyl groups in the side
chains in the regulatory protein QacR (25).
Compared with the binding of Cip, R6G, and Et, the binding
of a negatively charged antibiotic, Naf, seemed to involve more
electrostatic interactions in our model (not shown). Phe664 is
the only hydrophobic residue close to the ligand. One of the
partially positively charged hydrogen atoms of the phenyl ring
of this residue is very close to the sulfur atom in the penicillin
nucleus. The other drug-protein interactions also appear
largely electrostatic or dipolar. The carboxylate group of the
penicillin nucleus of Naf appears to interact with the backbone
nitrogen of Gly720 as well as the side chain amide nitrogen of
FIG. 3. Simulated annealing omit maps of bound Cip (top) and
R6G (bottom) molecules in the central cavity (left) and at the periplas-
mic binding pocket (right). The electron density omit map (contoured
at 1.5 ) was calculated with a starting temperature of 2,000°K and by
excluding the bound ligand from the model.
FIG. 4. The periplasmic drug-binding pocket with five ligands. This
is a composite figure showing the locations of the ligands in the
periplasmic domain. The view is from the outside into the center of the
trimer, with the transmembrane domain at the bottom. The ligands
shown in stick models are Cip (gray), Et (orange), R6G (red), Naf
(yellow), and MC (blue). The portion of the protein constituting the
binding pocket (discussed in the text) is in deep blue. This figure and
the following three figures were drawn with PyMol (W. L. Delano,
PyMol Graphic System [www.pymol.org]).
FIG. 5. Interaction of Cip with amino acid side chains in the
periplasmic binding pocket of the N109A mutant AcrB. Amino acid
residues that are within 6 Å of any atoms of the ligand are shown.
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Gln577. These are reminiscent of the neutralization of ligand
charges by formally uncharged atoms mentioned above. The
carbonyl oxygen of the -lactam ring is not far from the back-
bone nitrogens of Pro718 and Asn719.
In the binding of the inhibitor, MC, Phe664, and Arg717
appear to provide hydrophobic contacts to the naphthylamide
and phenylalanine moieties, respectively, of MC. Again it is
surprising that there are no acidic residues near this ligand with
two positive charges, and participation of backbone oxygens
(for example, those of Pro718 and Leu828) may be involved.
The amino nitrogen of the Phe residue of MC is also not far
from the side chain oxygen of Ser715. Possibly the guanidium
group of the Arg residue in MC interacts with the -electron
cloud of the naphthylamide moiety within MC. Coupled with
the inhibitor binding in the periplasmic domain is an outward
movement of residues 650 to 659 located in the -helix (C3 of
reference 23) preceding the substrate-binding loop of residues
663 to 676. This shift is apparently caused by the 10-degree
rotation (or partial melting) of a large portion of this helix. The
movement is significant, with the Gln657 -carbon moving 3.6
Å and some of the side chain atoms moving nearly 8 Å. We
suspect that the movement of these residues, which is not seen
in the other ligand complexes, may contribute to the inhibition
of the transporter activity.
Drug binding to the central cavity. Drug molecules are also
bound to the central cavity. However, for those ligands previ-
ously examined for their interaction with the wild-type AcrB
protein (48), including R6G, Et, and Cip, the positions of
binding appeared to be somewhat different from those seen
earlier, although the significance of this difference is made
somewhat unclear by the limited resolution of our crystals.
Thus, these ligands, as well as Naf and MC, seem to bind close
to the center of the cavity-lining wall of each protomer, in
contrast to the position between protomers in the wild-type
protein (Fig. 6; also compare Fig. 1B with Fig. 1A). In other
words, most ligands are located close to the top of TM helices
5 and 6, although R6G and MC appear to bind to the location
somewhat to the left of the others (as viewed in Fig. 6, from the
center of the cavity), involving more strongly the participation
of residues at the end of TM helix 3 (such as F386 and F388).
Residues within about 6 Å of the bound Cip are shown, as an
example, in Fig. 7. The binding is very loose, yet in comparison
with the wild-type structure, the binding with the mutant pro-
tein appears to involve larger number of residues, including
Phe386, Phe388, Phe459, and Arg468.
The binding of Et and Naf (not shown) was similar to the
Cip binding. R6G was found at a position similar to Et bound
to the wild-type AcrB (48). Thus, the three R6G molecules are
only 3 Å apart from one another, indicating that these li-
gands interact strongly with each other. For the inhibitor MC
(not shown), Phe386 appears to provide hydrophobic contact.
The three MC molecules also appear to interact strongly with
each other here, as each of them is separated by only about 5
Å from the others. In our model, the MC molecules appear to
be stretched vertically, in contrast to the highly bent confor-
mation found in the periplasmic binding site.
MIC determination in strains with plasmid-driven expres-
sion of AcrB. To confirm that the ligand binding observed had
functional significance, we mutated the residues near the li-
gand-binding sites and measured MICs in strains expressing
these site-directed mutants of AcrB. Initial studies were car-
ried out with recombinant plasmids containing only the mu-
tated acrB genes. These experiments, however, often gave non-
reproducible results. Overexpression of AcrB alone, without
the parallel overexpression of AcrA, apparently often leads to
variable drug susceptibility patterns, possibly because of the
misfolding of the membrane protein, AcrB (H. I. Zgurskaya,
personal communication; O. Lomovskaya, personal communi-
cation). To avoid these complications, in the following exper-
iments we always used recombinant plasmids expressing both
AcrA and AcrB from the same promoter, a strategy pioneered
by other laboratories (for an example, see reference 40).
Mutations in the periplasmic domain of AcrB. As described
earlier, the mutant N109A protein produced nearly wild-type
levels of resistance to most inhibitors, except tetracycline, ac-
riflavine, and SDS (Table 2), when expressed together with
AcrB in the acrA::cat acrB::kan acrD host strain HNCE1b.
Thus, the mutant transporter was largely functional. These
results can be compared with the recent study (24) of the
function of N109C mutant AcrB, which reported that the re-
sistance to tetracycline and acriflavine was decreased. With the
N109C mutant, however, decreased resistance to erythromycin
and unaltered resistance to SDS are reported; it is unclear
whether this difference between N109A and N109C is related
to the spontaneous disulfide cross-linking between protomers
seen in the latter mutant (24).
We converted into alanine those residues that appear to be
close (usually within 6 Å) to the ligands in the structural mod-
els. These include D566, which forms the “bottom” (i.e., the
end closest to the membrane surface) of the binding pocket, as
well as F664 and F666, which are parts of a periplasmic loop
FIG. 6. The wall of the central cavity with five ligands. This is a
composite figure showing the locations of the bound ligands in the
central cavity. The view is from the center of the cavity toward the wall,
with the periplasmic domain at the top. The ligands are shown in stick
models in the same colors as in Fig. 3: thus, Cip (gray), Et (orange),
R6G (red), Naf (yellow), and MC (blue).
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that connects the AcrB PC1 and PC2 domains and form the
“right” wall of the pocket (viewed from outside the trimer as in
Fig. 4), and S715 and R717, which form the “left” wall. We also
included E673, which is close to the bottom of the pocket,
although it seems somewhat more distant from the ligands in
our model. Finally, as a control, we mutated W859, which is
located in the periplasmic domain in the c15 segment pre-
ceding TM8 but outside the binding pocket. Most of the mu-
tations were generated in the background of both the wild-type
acrB gene and the N109A mutant acrB. We compared the
resistance levels caused by the various double-mutant proteins
with those generated by the parent, single mutant N109A. As
seen in Table 2, conversion of these residues to alanine
strongly decreased the resistance to various agents compared
with the results seen with the N109A parent protein except
D566 and S715. With many mutations (see F664, F666, and
E673) resistance to practically all of the agents was compro-
mised, whereas with R717 a strong effect was seen only with
novobiocin. These results suggest strongly that the residues
surrounding this periplasmic binding site are required for the
transport, and presumably the binding, of substrates, at least in
the N109A mutant AcrB transporter. We note that all of these
mutant proteins were produced at levels close to that of the
parent proteins (Fig. 8A). Although there were small varia-
tions in the level of expression, these are not expected to
produce large (fourfold or larger) differences in MIC as noted
in Table 2, because calculations using the parameters derived
in reference 38 indicate that decreasing tetracycline MIC from
8 to 2 g/ml requires the loss of more than 80% of the trans-
porter if its specific activity is unaltered.
We further examined whether the same residues are in-
volved in the transport catalyzed by the wild-type transporter.
As seen in Table 2, conversion to alanine of those residues
found to be important in the N109A background, including
F664, F666, E673, and R717, resulted in significant decreases
of resistance to at least a few agents. Interestingly, the R717A
mutation, which decreased only the novobiocin MIC in the
N109A background, decreased the MIC of both novobiocin
and acriflavine in the wild-type background. We point out also
that the W859A mutation, used as a negative control, did not
alter the MIC of any agents. Again, all transporters were ex-
pressed to a level similar to that of the wild-type protein (Fig. 8B).
Site-directed mutagenesis of the AcrB central cavity phenyl-
alanine residues F386, F388, F458, and F459. The wild-type
AcrB crystal structure in the presence of four different sub-
strates (R6G, Et, dequalinium [Dq], and Cip) (48) suggested
that residues F386, F388, F458 and F459 may be involved in
drug binding. We examined the role of these residues, which
are located at the wall of the upper part of the central cavity,
by converting them into alanine.
All of the single substitutions resulted in transporters that
retained most of the activity towards the tested molecules
(Table 2, footnote b), although twofold decreases in MICs
were frequently seen for tetracycline, erythromycin, Dq, and
acriflavine. These decreases are likely to be significant, as the
MIC determination was repeated at least five times and repro-
ducible values were obtained. Similar results were obtained
with double substitutions F386A/F388A or F458A/F459A (Ta-
ble 2, footnote b). However, with the quadruple-substitution
mutant F386A/F388A/F458A/F459A, there was a fourfold de-
crease in resistance to taurocholate and acriflavine (Table 2).
As shown in Fig. 8A, Western blot analysis showed that all the
mutant proteins were expressed at levels comparable to that of
the wild-type proteins expressed by pAcrAB (Table 1).
Mutation of the charged residues K29 and D101. Charged
residues are known to play an important role among multidrug
transporters. Residue K29, located close to the internal end of
the vestibule, was found within 6 Å of the ligands R6G and Cip
(48). Substitution of residue K29 with the neutral residue ala-
nine resulted in a significant decrease in resistance to acrifla-
vine and a small, but probably significant, twofold decrease in
MICs of novobiocin, tetracycline, erythromycin, Et, and Dq
(Table 2).
We (48) pointed out the possible electrostatic interaction for
the dicationic disinfectant Dq with the acidic amino acid res-
idue D101, located in the ceiling of the AcrB central cavity. As
shown in Table 2, when D101 was replaced with the neutral
amino acid alanine it caused only a modest, twofold reduction
in Dq MIC. There was also a small decrease in the MIC of
novobiocin and erythromycin. However, the strain expressing
this mutant AcrB showed increased susceptibility to acriflavine
and tetracycline. The latter results are consistent with a recent
report (24) of a study in which the authors replaced residue
D101 with the uncharged amino acid cysteine and found de-
creased MICs of acriflavine, tetracycline, chloramphenicol,
and erythromycin. Western blot analysis showed that D101A
and K29A mutant proteins were expressed at levels compara-
ble to that of the wild-type AcrB (Fig. 8). Although charged
FIG. 7. Interaction of Cip with amino acid side chains in the central
cavity of the N109A mutant AcrB. Amino acid residues within 6 Å of
any atoms of Cip (in gray) are shown in green.
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residues within the TM helices are known to be crucial in drug
efflux (1, 10), these results suggest that such residues outside
the TM helices may also play significant roles in the efflux
process, presumably in ligand-binding step(s).
Et accumulation assay. To confirm the MIC results, we
examined the intracellular accumulation of Et into intact cells
expressing various constructs of AcrB. While the acrA::cat
acrB::kan acrD E. coli strain HNCE1b (pAcrB) rapidly ac-
cumulated Et owing to the virtual absence of its active efflux,
HNCE1b strain trans-complemented with the wild-type acrAB
genes (plasmid pAcrAB) showed a much slower accumulation,
presumably as a result of efflux (Fig. 9). As expected, strains
expressing mutant AcrB proteins with substitutions F664A/
N109A (Fig. 9B) and F666A/N109A (Fig. 9A) showed higher
rates of Et accumulation compared to that with the wild-type
AcrB, while strains with AcrB containing single substitution
F664A or F666A accumulated the dye somewhat less rapidly.
These results show that alterations of F664 or F666 in the
periplasmic binding site decrease the Et pumping activity of
AcrB and that this defect becomes even more serious when an
N109A mutation exists in the background.
DISCUSSION
The altered drug binding in N109A mutant AcrB. We mu-
tated the Asn109 residue, whose side chain protrudes into the
narrow central pore of the periplasmic domain of AcrB (Fig.
1A), into alanine, with a one-carbon side chain. Although this
did not produce a wide pore that would accommodate the
ligands easily, the drugs now bound to a new site, correspond-
ing to the external depression of the periplasmic domain, in
FIG. 8. Western blot analysis of the expression of AcrA and the mutant AcrB proteins. Total protein extracts of E. coli HNCE1b (acrA::cat
acrB::kan acrD) harboring the different plasmid constructs based on plasmid pAcrAB were separated by SDS-polyacrylamide gel electrophoresis
(7.5% gel) and probed with polyclonal anti-AcrA antibodies (lower panels) or with polyclonal anti-AcrB antibodies (upper panels). Panels A and
B show different sets of mutants; for example, the left part of panel A shows mostly double mutants containing N109A.
FIG. 9. Et accumulation by intact cells of E. coli HNCE1b express-
ing various versions of AcrB protein together with the wild-type AcrA
(except cells containing pAcrB). Cells were grown in LB, induced with
0.1 mM of IPTG for 1 h, harvested, washed, and resuspended in
phosphate buffer as described in Materials and Methods. Accumula-
tion time course was monitored with a spectrofluorometer. Et was used
at a final concentration of 5 M. Panel A shows AcrB mutants con-
taining the F666A mutation; Panel B shows those containing the
F664A mutation.
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addition to the wall of the central cavity (Fig. 1B). This may be
important, because the large periplasmic domains of the RND
transporters MexB, MexD, AcrB, and AcrD have been impli-
cated in substrate recognition and specificity by using chemical
mutagenesis (19, 20) or by engineering pump chimeras, first by
Elkins and Nikaido (8) and Tikhonova et al. (39) and later
confirmed by Eda et al. (7), and yet periplasmic substrate-
binding sites have not so far been observed by crystallography.
Drug binding to the periplasmic site seems to involve a
larger number of amino acid side chains (Fig. 5), in comparison
with the binding to the central cavity of the wild-type AcrB
(48). Furthermore, there are likely electrostatic interactions
between the atoms of ligands and the protein atoms. Yet the
binding pocket is quite loose. Similar expansive binding pock-
ets and loose binding have been reported earlier for regulators
of multidrug transport protein expression, based on X-ray
structures with good resolution (34, 35, 51). For example, in
the Et complex of the QacR protein (PDB file 1JTY) (34), only
two atoms of the protein are within 3 Å of any atom of the
ligand, and substantial portions of the aromatic rings of ty-
rosine and phenylalanine residues that sandwich the ligand are
5 to 6 Å away from the ligand, a situation similar to that found
in this work. Neyfakh (27) argued persuasively that the tight
binding of hydrophilic ligands is required only because of the
energy needed to remove such ligands from the extensively
H-bonded environment of water and that such tight binding is
not needed for lipophilic ligands, because no such energy is
needed to remove them from water.
In the central cavity, the positions of binding often appeared
to be somewhat different from those seen in the wild-type AcrB
(48). The extensive nature of binding sites for lipophilic ligands
is often known to lead to the situation where a single ligand can
bind in multiple positions or orientations. This was found for
example with the pig odorant binding protein (45) and PXR
xenobiotic resistance regulator (46). There are also data sug-
gesting the presence of multiple ligand-binding sites in various
multidrug resistance transporters (6, 14, 22, 31, 36, 44). Our
finding of drug binding to different positions in the central
cavity in the wild-type and the mutant AcrB and the inability to
abolish activity by single (or even double) mutations also seem
to emphasize the flexibility of substrate binding sites within this
huge, possibly composite (47) space.
Site-directed mutagenesis data suggest a functional role for
the periplasmic site. We showed in this study that the conver-
sion, into alanine, of some of the residues surrounding the
bound ligands in the periplasmic sites, such as F664, F666, and
E673, made the AcrB pump less efficient with most substrates.
Importantly, the same mutations also decreased the activity of
the AcrB protein without the background N109A mutation,
although the range of substrates affected became somewhat
more limited (Table 2). These results suggest strongly that the
periplasmic binding site newly discovered by the crystallo-
graphic study of N109A AcrB transporter is physiologically
relevant, not only in the N109A mutant protein but also in the
wild-type AcrB.
As with any site-directed mutagenesis study, we cannot ex-
clude formally the possibility that the conversion of these res-
idues into alanine affected the activity because of alteration of
protein conformation rather than its direct effect on ligand
binding. This seems unlikely, because transporter structures
are amazingly flexible; for example, the complete cysteine mu-
tagenesis of the lactose transporter LacY uncovered only 6
residues that were essential out of more than 400 residues (13).
Furthermore, side chains of most of the residues altered in this
study, both in the central cavity and in the periplasmic pocket,
are extending out into hollow spaces in the apoprotein struc-
ture (23, 48) and are therefore unlikely to affect the global
conformation of the protein. Nevertheless, we are currently
trying to examine ligand binding kinetics to settle this issue in
an unambiguous manner.
Implications for the substrate export pathway. Since the
binding of the drugs to the periplasmic site was seen only with
the N109A mutant AcrB, its physiological relevance may be
questioned. However, this second site is likely to participate in
the normal pathway of substrate transport for the following
reasons. (i) As discussed above, site-directed mutagenesis of
the residues involved in the periplasmic binding decreased the
MIC of various ligands. (ii) Mao et al. (19) isolated spontane-
ous mutants of P. aeruginosa MexD (a close homolog of AcrB)
that acquired the ability to extrude dianionic -lactams. Some
of the mutants have amino acid substitutions right in the area
of the periplasmic binding site, including N673T, which corre-
sponds to Thr676 in AcrB, at the lower end of the substrate
binding pocket (Fig. 5), as well as E89K, corresponding to
Gln89 in AcrB, at the bottom of the periplasmic depression.
Furthermore, random mutagenesis of P. aeruginosa MexB, an
AcrB homolog, showed that R716H mutation alters the sub-
strate specificity (20); this residue corresponds to Arg717 of
AcrB, that seems to play a major role in the periplasmic bind-
ing (Fig. 5). The contribution of the periplasmic binding site to
the normal export pathway is also consistent with the earlier
genetic data mentioned above, showing that the substrate spec-
ificity of the RND pumps is determined largely by the periplas-
mic domain.
Our current data, however, do not allow us to conclude
whether the two binding sites function sequentially or concom-
itantly. In the former case, we favor the hypothesis that the
periplasmic binding occurs after the initial binding of ligands to
the central cavity, because the periplasmic binding seems to be
somewhat tighter than the binding to the central cavity. Pos-
sibly the slightly altered conformation of the N109A mutant
transporter mimics one of the transient conformations of AcrB
during drug transport, and the periplasmic binding in the
N109A AcrB thus may mimic the ligand-binding step that
occurs after the binding to the central cavity (48). It is not
known how the ligands would travel between the central cavity
and the periplasmic depression area. However, the periplasmic
domain contains, in addition to the various cavities already
mentioned, a possible passageway that we call a “fissure” (Fig.
1A) between the C-terminal loop domain on the outside and
the N-terminal loop domain on the inside (23); possibly the
ligands may migrate through these fissures. This is suggested
by the mutant studies of Mao et al. (19), which also identified
several residues at the entrance of the fissure as those affecting
the substrate specificity of MexD, an AcrB homolog. We sus-
pect that the fissure area may open up more when a drug
molecule moves from the central cavity to periplasmic pocket.
Alternatively, the substrates may not move between the two
sites, and the simultaneous occupancy of the two sites may be
necessary to activate the pump. In the mammalian P-glyco-
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protein, evidence suggests that there is an allosteric modula-
tor-binding site that is separate from (but possibly overlaps)
the two substrate-binding sites (6). In any case, these models
are entirely speculative at present and there are no data that
exclude other models (for example, ligand export through the
central pore, as advocated by another laboratory) (24).
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